|Indication|| ‒ Healing of all grades of erosive esophagitis (EE)
‒ Maintaining healing of EE
‒ Treating heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD)
|Status||First- to File (FTF), Par received final approval on April 2017.|
|Product Advantages|| ‒ FTF, 180-day market exclusivity right in the USA.
‒ settled with Takeda, and will launch in 2022.
|Potential Market||The market value of branded drug is about $1 billion per year. Par, a commercialization partner of Handa, is expected to occupy a certain market share.|